4.6 Article

Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes

期刊

JAMA CARDIOLOGY
卷 6, 期 12, 页码 1371-1379

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamacardio.2021.3370

关键词

-

资金

  1. American Heart Association's Atrial Fibrillation Strategically Focused Research Network [18SFRN34110369, 18SFRN34110082, 20SCG35540037]
  2. Clinical Translational Science Award from the National Institutes of Health [UL1 TR002243]
  3. National Center for Advancing Translational Sciences
  4. National Institutes of Health [1RO1HL092577, K24HL105780, 1R01HL139731, 1R01 HL138737, 1T32 HL139439]
  5. American Heart Association [18SFRN34110369, 18SFRN34110082, 18SFRN34250007]
  6. Foundation Leducq [14CVD01]
  7. Bayer AG and IBM
  8. Atrial Fibrillation Collaborative from the American Heart Association [20SCG35540037]

向作者/读者索取更多资源

Genetic testing in patients with early-onset AF identified a disease-associated variant in 10% of participants, with a higher prevalence in those diagnosed before 30 years of age. Most pathogenic/likely pathogenic variants are located in genes associated with cardiomyopathy.
IMPORTANCE Early-onset atrial fibrillation (AF) can be the initial manifestation of a more serious underlying inherited cardiomyopathy or arrhythmia syndrome. OBJECTIVE To examine the results of genetic testing for early-onset AF. DESIGN, SETTING, AND PARTICIPANTS This prospective, observational cohort study enrolled participants from an academic medical center who had AF diagnosed before 66 years of age and underwent whole genome sequencing through the National Heart, Lung, and Blood Institute's Trans-Omics for Precision Medicine program. Participants were enrolled from November 23, 1999, to June 2, 2015. Data analysis was performed from October 24, 2020, to March 11, 2021. EXPOSURES Rare variants identified in a panel of 145 genes that are included on cardiomyopathy and arrhythmia panels used by commercial clinical genetic testing laboratories. MAIN OUTCOMES AND MEASURES Sequencing datawere analyzed using an automated process followed by manual review by a panel of independent, blinded reviewers. The primary outcome was classification of rare variants using American College of Medical Genetics and Genomics criteria: benign, likely benign, variant of undetermined significance, likely pathogenic, or pathogenic. Disease-associated variants were defined as pathogenic/likely pathogenic variants in genes associated with autosomal dominant or X-linked dominant disorders. RESULTS Among 1293 participants (934 [72.2%] male; median [interquartile range] age at enrollment, 56 [48-61] years; median [interquartile range] age at AF diagnosis, 50 [41-56] years), genetic testing identified 131 participants (10.1%) with a disease-associated variant, 812 (62.8%) with a variant of undetermined significance, 92 (7.1%) as heterozygous carriers for an autosomal recessive disorder, and 258 (20.0%) with no suspicious variant. The likelihood of a disease-associated variant was highest in participants with AF diagnosed before the age of 30 years (20 of 119 [16.8%; 95% CI, 10.0%-23.6%]) and lowest after the age of 60 years (8 of 112 [7.1%; 95% CI, 2.4%-11.9%]). Disease-associated variants were more often associated with inherited cardiomyopathy syndromes compared with inherited arrhythmias. The most common genes were TTN (n = 38), MYH7 (n = 18), MYH6 (n = 10), LMNA (n = 9), and KCNQ1 (n = 8). CONCLUSIONS AND RELEVANCE In this cohort study, genetic testing identified a disease-associated variant in 10% of patients with early-onset AF (the percentage was higher if diagnosed before the age of 30 years and lower if diagnosed after the age of 60 years). Most pathogenic/likely pathogenic variants are in genes associated with cardiomyopathy. These results support the use of genetic testing in early-onset AF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据